U.S. RESEARCH ROUNDUP-Factset Research Systems, Mirati Therapeutics, Twilio

Re/Max Holdings

26/09/2022 08:16

Sept 26 (Reuters) - Wall Street securities analysts revised their ratings and price
targets on several U.S.-listed companies, including Factset Research Systems, Mirati
Therapeutics and Twilio, on Monday. 
    HIGHLIGHTS
                 * Factset Research Systems Inc  FDS.N : Jefferies cuts target price to $427 from
 $444 
 
                 * Mirati Therapeutics Inc  MRTX.O : JP Morgan cuts target price to $94 from $109 
 
                 * Twilio Inc  TWLO.N : Piper Sandler cuts target price to $113 from $122 
 
 Following is a summary of research actions on U.S. companies reported by Reuters on Monday.
Stock entries are in alphabetical order. 
                 * Calamp Corp  CAMP.O : Jefferies cuts target price to $8 from $10.5 
 
                 * Celanese Corp  CE.N : Credit Suisse cuts target price to $86 from $105 
 
                 * Cs Disco Inc  LAW.N : Jefferies cuts target price to $12 from $25 
 
                 * Factset Research Systems Inc  FDS.N : Jefferies cuts target price to $427 from
 $444 
 
                 * Fidelity National Information Services Inc  FIS.N : Jefferies cuts PT to $95 from
 $110 
 
                 * GXO Logistics Inc  GXO.N : Credit Suisse cuts target price to $56 from $65 
 
                 * Health Catalyst Inc  HCAT.O : BTIG cuts target price to $21 from $25 
 
                 * Lennar Corp  LEN.N : JP Morgan cuts target price to $73 from $80 
 
                 * Mirati Therapeutics Inc  MRTX.O : JP Morgan cuts target price to $94 from $109 
 
                 * Re/Max Holdings Inc  RMAX.N : Jonestrading cuts target price to $28 from $34 
 
                 * Twilio Inc  TWLO.N : Piper Sandler cuts target price to $113 from $122 
 
                 * Viatris Inc  VTRS.O : JP Morgan cuts target price to $13 from $15 
 
 (Compiled by Bengaluru Newsroom; Editing by Dhanya Ann Thoppil)
 ((Diaries@thomsonreuters.com))